key: cord-0683928-hbuu1shn authors: Okumura, Nobumasa; Tsuzuki, Shinya; Saito, Sho; Hattori, Shin-ichiro; Takeuchi, Junko S.; Saito, Tomoya; Ujiie, Mugen; Hojo, Masayuki; Iwamoto, Noriko; Sugiura, Wataru; Mitsuya, Hiroaki; Ohmagari, Norio title: Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan date: 2022-04-22 journal: J Infect Chemother DOI: 10.1016/j.jiac.2022.04.018 sha: e591f983ff1ed3085f27c53c317912c8d17c4a26 doc_id: 683928 cord_uid: hbuu1shn The Omicron variant of severe acute respiratory syndrome coronavirus 2 has amino acid mutations in its spike proteins, which may allow it to evade immunity elicited by vaccination. We examined the neutralising activity and S1-IgG titres in patients with breakthrough infections caused by the Omicron variant after two doses of vaccination. We found that neutralising activity was significantly lower for the Omicron variant than for the Wuhan strain. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant. diagnosis was 130 days (interquartile range [IQR] : 117-134). Two patients were asymptomatic, while eight patients had mild disease that did not require oxygen supplementation. One patient received sotrovimab (No. 9); no patients received corticosteroids or died (Supplementary Table S1 ). The levels of anti-SARS-CoV-2 S1-IgG antibodies were determined using the HISCL anti-SARS-CoV-2 immunoassay (Sysmex, Kobe, Japan), as previously described (4 We compared NT50 values for the ancestral lineage and the Omicron variant using the Wilcoxon signed-rank test, using the first samples from each patient. We also examined correlations between the S1-IgG titres and NT50 values for both variants, using the Spearman rank correlation coefficient. NT50 values lower than 40 were regarded as 39 in statistical analysis. In total, 25 and 31 blood samples were obtained from 10 patients and analysed for S1-IgG titres and NT50 values, respectively. In the initial samples collected at a median of 4 days (IQR: [3] [4] [5] after disease onset or diagnosis, NT50 values were detectable for the ancestral lineage; however, no samples showed detectable neutralisation of the Omicron variant ( Figure 2 ). NT50 values of the initial samples were significantly lower for the Omicron variant than for the ancestral lineage (p<0.001). Additionally, the median S1-IgG titre was 770. The median time from the second dose of mRNA vaccine to diagnosis or onset in patients in this study was 130 days. After diagnosis or onset, S1-IgG titres increased in all patients. In a J o u r n a l P r e -p r o o f previous study, S1-IgG titres reached a peak 28 days after the first dose (i.e., 7 days after the second dose) of BNT162b2 and declined linearly thereafter(12); thus, S1-IgG titres in our patients might have decreased over time but recovered upon infection with the Omicron variant. Our results also indicated that a higher S1-IgG titre was associated with higher NT50 values for both the ancestral lineage and the Omicron variant. This correlation is consistent with previous findings concerning positive correlations of neutralising activity with S-or S1-IgG titres after vaccination(12) or infection (11) . While there are only a limited number of facilities that can analyse neutralizing activity, we might predict neutralizing activity by measuring S1-IgG titres. The limitation of our study is that a smaller number of patients (all returnees from travel abroad) were analysed than in a previous study (7) . Although the smaller sample size may affect the reliability of the correlation between S1-IgG titres and NT50 values, our study showed a high correlation coefficient. In this study of 10 patients with breakthrough infections of the Omicron variant in Japan, we found that initial samples collected after disease onset or diagnosis exhibited significantly lower neutralising activity for the Omicron variant than for the ancestral lineage. Notably, no samples showed detectable neutralisation for the Omicron variant. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant in this study time course. World Health Organization. Classification of Omicron (B1.1.529): SARS-CoV-2 Variant of The first eleven cases of SARS-CoV-2 Omicron variant infection in Japan: A focus on viral dynamics. Global Health & Medicine Omicron (B.1.1.529) Variant A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization Plasma neutralization of the SARS-CoV-2 Omicron variant Implication of SARS-CoV-2 immune escape spike variants on secondary and vaccine breakthrough infections Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape NOkumura, ST, SS, NI, and NOhmagari designed the study. NOkumura, ST, SS, MU, MH, and NI implemented the study and collected data. SH determined the neutralising activity. JT and TS were responsible for the mutational analysis. NOkumura, ST, and SS wrote the first draft of the manuscript. WS, HM, and NOhmagari supervised this study. All authors revised the manuscript and approved the final version. The authors declare no conflicts of interest associated with this manuscript.